FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

hours per response: 0.5

1. Name and Address of Reporting Person* Thiel Carsten						2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC [ALXN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET						3. Date of Earliest Transaction (Month/Day/Year) 02/06/2017									X Officer (give title Officer Specify below) EVP, Chief Commercial Officer				
(Street) NEW HAVEN CT 06510 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tabl	le I - N	on-Deriv	/ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or	Bene	eficia	ally Owr	ed			
1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/						Execution Date			Transaction Dispos Code (Instr.			ities Acquired (A) o d Of (D) (Instr. 3, 4 a			5) Seci Ben Owr	nount of irities eficially ed Following orted	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) (D)	Pr Pr	ice	Tran	saction(s) r. 3 and 4)		(111501.4)					
Common Stock, par value \$.0001 per share 02/06/20						.017			S		165 ⁽¹⁾ D S		\$	125.6	9 ⁽²⁾	30,268	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Security (Instr. 3)	Derivative Security Price of Derivative Security Date (Month/Day/Year) (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) 8			Code (8)	ransaction of ode (Instr. Derivative		ative rities ired osed . 3, 4	6. Date Exercisable and Expiration Date Expiration Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ount nber	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$125.00 \$125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

/s/ Michael Greco, Attorney-in-02/08/2017 Fact for Carsten Thiel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.